1 2-Topic Imaging Workshop: (1)Standards for Imaging Endpoints in Clinical Trials (2) Manufacturing of PET Radiopharmaceutical Products Wendy R. Sanhai,

Slides:

Advertisements

Similar presentations

Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.

Advertisements

Development of Guidance Documents Jennifer Scharpf, M. P. H

Transition to Inspections: USP, 21 CFR 212, And Beyond? Panel Discussion Ravi S. Harapanhalli, Ph.D Louis Marzella, MD Ravindra Kasliwal, Ph.D Wendy Sanhai,

Introduction to Regulation

Special Topics in IND Regulation

Radioactive Drug Research Committee

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

AMERICAN COLLEGE OF RADIOLOGY March 23, OUR MISSION To foster the ongoing development of widely acceptable consistent imaging.

DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,

Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.

Overview of FDA's Regulatory Framework for PET Drugs

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.

1 George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations Perceptive Informatics Workings of the SNM Clinical Trials Network Centralized.

PhUSE Computational Science Working Groups Solutions Through Collaboration.

UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.

Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

Beyond and Decisions: From Problem Formulation to Dose- Response.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Focus on Phase 2 FSMA Implementation

FDA Public Meeting on Electronic Records and Signatures June 11, 2004 Presentation of the Industry Coalition on 21CFR Part 11 Alan Goldhammer, PhD Chair.

Overview of FDA's Regulatory Framework for PET Drugs

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Large Multicenter Clinical Trials George.

Welcome and Introduction Lee S. Simon, MD Division Director Analgesic, Anti-inflammatory and Ophthalmologic Drug Products ODEV/CDER.

OHRP Guidance and Policy Development Process Secretary’s Advisory Committee on Human Research Protections Meeting October 27, 2008 Irene Stith-Coleman,

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

Inclusion of Women in Clinical Trials & Drug Development Regulatory Perspective Ameeta Parekh, Ph.D. R&D Director Office of Women’s Health Food & Drug.

10 CFR Part 37 Self-Assessment Retrospective Program Review to Ensure an Effective and Efficient Framework for the Security of Radioactive Material Organization.

REGULATION OF COMBINATION PRODUCTS Mark A. Heller Wilmer Cutler Pickering Hale and Dorr LLP MassMEDIC Combination Product Program, March 28, 2006.

Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

Progress of the SNM Clinical Trials Network Michael Graham, PhD, MD Clinical Trials Network Co-Chair SNM President 1.

FDA Office of Orphan Products Development

1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.

1 Imaging Community Critical Need #1: Standardized and Harmonized Multisite Imaging George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations.

Chief, Gene Therapy Branch

The Clinical Trials Network for European Manufacturers Sally Schwarz, MS, RPh, BCNP Chair, Manufacturer’s Registry Sub-Committee SNM Clinical Trials Network.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.

RDRC Membership: SNM Suggestions Mathew L. Thakur, Ph.D. President Society of Nuclear Medicine.

ICH Quality Topics Update

1 A continued FDA Concern about Imaging Based Drug Trials Society of Nuclear Medicine Albuquerque, Feb 1-2, 2009 Orhan H Suleiman MS PhD, FAAPM Senior.

PhUSE Computational Science Working Groups Solutions Through Collaboration.

Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.

FSMA Communications and Engagement for International Stakeholders March 21, 2016 Julie Moss, PhD, RD Deputy Director, International Affairs Staff, Center.

ACRIN EISC Experimental Imaging Sciences Committee (EISC) David Mankoff, MD, PhD Experimental Imaging Sciences Committee Chair Professor of Radiology University.

© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.

Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.

Nonclinical Studies Subcommittee John Doull, M.D., Ph.D., Chair Advisory Committee for Pharmaceutical Science November 15, 2000.

Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.

Clinical Review Process for New Drug Development and Application

U.S. FDA Center for Devices and Radiological Health Update

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

The Information Professional’s Role in Product Safety

Nat. Rev. Clin. Oncol. doi: /nrclinonc

PhUSE Computational Science

PhUSE Computational Science Working Groups

FDA 21 CFR Part 11 Overview June 10, 2006.

Patient Involvement in the Development and Safe Use of

Presentation transcript:

1 2-Topic Imaging Workshop: (1)Standards for Imaging Endpoints in Clinical Trials (2) Manufacturing of PET Radiopharmaceutical Products Wendy R. Sanhai, Ph.D., M.B.A Senior Scientific Advisor Office of the Commissioner, FDA Society of Nuclear Medicine Albuquerque, Feb 1, 2009

Catalyst and Next Steps The Prescription Drug User Fee Act (PDUFA) IV signed in 2007 called for the development of a guidance to address “Imaging Standards for Use as an End Point in Clinical Trials” Two-day scientific workshop, co-sponsored with SNM, RSNA, with key input from NCI/CIP

PET cGMP Regulations FDA issued final rule for cGMP for PET drugs (21 CFR part 212) in the Federal Register of December 10, 2009 (74 FR 65409). Concurrently, FDA also announced the availability of a guidance entitled ‘‘PET Drugs—Current Good Manufacturing Practice (cGMP)” to help PET drug producers better understand FDA’s thinking regarding compliance with the new PET cGMP requirements.

Workshop Objectives Bring together pharmaceutical/device industries, CROs, imaging core laboratories, academia, government agencies, and other professional organizations toward: –Identify and develop standards for the use of imaging to determine endpoints in clinical trials –Inform regulatory guidance development –Share regulatory perspectives on cGMP for PET imaging: review on the 21 CFR Part 212 cGMP regulation and the associated guidance –Share lessons learned and expectations for Chemistry, Manufacturing and Controls (CMC) in regulatory submissions –Share regulatory perspectives on PET radiopharmaceuticals registration and use in multicenter clinical trials

Day 1: General Issues of Imaging Standards in Clinical Trials Image Acquisition & Analysis: quality control concepts, equipment and software, phantoms Image Interpretation: Local vs central read design, sources and solutions to read variability Data Management: display, storage, transmission

6 Day 2: Manufacturing of PET Radiopharmaceutical Products Regulatory framework for PET drugs: 21 CFR Part 212 regulations establishing the Current Good Manufacturing Practice (cGMP) for PET drugs Considerations for Chemistry Manufacturing and Controls (CMC) for: –Investigational New Drug Application (IND) –New Drug Application (NDA) –Radioactive Drug Research Committee (RDRC) FDA Perspective on PET Radiopharmaceuticals Registration & Manufacturing Industry Perspective on PET Drug Manufacturing Lessons learned in multi-center trials: –National Cancer Institute: FLT F-18 IND and F-18 NaF NDA –American College of Radiology Imaging Network –Society of Nuclear Medicine –Academy of Molecular Imaging

Next Steps Outreach to stakeholders Complete concept paper to stimulate discussion for future guidance: –“Essential Imaging Standards for Successful Development of Imaging End Points in Clinical Trials”

8 Thank You!